Whitney Ijem

Q: How accurate are Whitney Ijem's stock ratings?

About 38% of Whitney's ratings were profitable over a one-year hold, with an average return of -5.2% per rating, measured by 13Foresight from historical prices.

Q: How is Whitney ranked?

Whitney Ijem is ranked #2755 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Canaccord Genuity

Wall Street Analyst

★★☆☆☆

#2755

on 13Foresight · ranked by our own returns

38%

Success Rate

-5.2%

Average Return

35 of 91 calls profitable · -6.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 38% of Whitney Ijem's ratings turned a profit when each position was held for 1 year — averaging -5.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

130 Buy 9 Hold 0 Sell

Whitney's Stock Coverage 35 ratings · 2026-11-08

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
WVE Wave Life Sciences	Oct 29, 2026	BUY	Strong Buy +443.6% avg upside 30 analysts	$44.00 1125.67% Upside	-7.0%	·
PHAR Pharming Group	Oct 29, 2026	BUY	Strong Buy +223.0% avg upside 4 analysts	$41.00 235.25% Upside	+0.8%	·
BEAM Beam Therapeutics	Oct 29, 2026	BUY	Strong Buy +91.1% avg upside 25 analysts	$79.00 190.09% Upside	-10.3%	·
BMRN BioMarin Pharmaceutical	Oct 29, 2026	BUY	Strong Buy +63.6% avg upside 52 analysts	$114.00 94.75% Upside	-2.5%	·
NGNE Neurogene	Oct 28, 2026	BUY	Buy +79.5% avg upside 24 analysts	$166.00 502.62% Upside	-12.4%	·
ALNY Alnylam Pharma	Oct 27, 2026	BUY	Strong Buy +76.3% avg upside 53 analysts	$429.00 160.01% Upside	-31.2%	·
GUTS Fractyl Health, Inc.	Oct 23, 2026	BUY	Strong Buy +1326.9% avg upside 7 analysts	$39.00 3893.81% Upside	-12.7%	·
MAZE Maze Therapeutics, Inc.	Oct 19, 2026	BUY	Strong Buy +102.8% avg upside 14 analysts	$75.00 138.23% Upside	+9.5%	·
QNRX Quoin Pharmaceuticals	Oct 19, 2026	BUY	Strong Buy +478.5% avg upside 10 analysts	$18.00 296.55% Upside	+1.0%	·
RCKT Rocket Pharmaceuticals	Oct 07, 2026	BUY	Buy +546.4% avg upside 30 analysts	$10.00 309.80% Upside	-2.8%	·
BBIO BridgeBio Pharma	Oct 06, 2026	BUY	Strong Buy +26.0% avg upside 36 analysts	$106.00 41.51% Upside	+10.9%	·
OCGN Ocugen	Sep 29, 2026	BUY	Strong Buy +1211.8% avg upside 17 analysts	$11.00 1465.44% Upside	-35.5%	·
ARCT Arcturus Therapeutics	Sep 24, 2026	BUY	Buy +175.7% avg upside 36 analysts	$20.00 81.25% Upside	-26.7%	·
VRTX Vertex Pharmaceuticals	Sep 23, 2026	HOLD	Strong Buy -20.5% avg upside 62 analysts	$442.00 20.96% Downside	+5.1%	·
RARE Ultragenyx Pharmaceutical	Sep 18, 2026	BUY	Strong Buy +193.8% avg upside 36 analysts	$39.00 142.20% Upside	+18.3%	·
BLTE Belite Bio, Inc. ADR	Sep 04, 2026	BUY	Strong Buy +29.7% avg upside 11 analysts	$303.00 95.77% Upside	-20.6%	·
TSHA Taysha Gene Therapies	Aug 11, 2026	BUY	Strong Buy +241.8% avg upside 22 analysts	$17.00 311.54% Upside	-38.8%	·
TNYA Tenaya Therapeutics	Aug 06, 2026	BUY	Strong Buy +2621.8% avg upside 11 analysts	$5.00 1260.95% Upside	-49.5%	·
NTLA Intellia Therapeutics	Aug 06, 2026	BUY	Buy +187.2% avg upside 39 analysts	$49.00 292.99% Upside	+1.0%	·
RYTM Rhythm Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +39.2% avg upside 23 analysts	$154.00 66.34% Upside	-5.1%	·
PVLA Palvella Therapeutics	Aug 05, 2026	BUY	Strong Buy +17.8% avg upside 28 analysts	$232.00 58.64% Upside	+12.5%	·
PASG Passage Bio	Apr 21, 2026	BUY	Buy +407.4% avg upside 14 analysts	$23.00 566.72% Upside	-45.1%	·
KRYS Krystal Biotech	Feb 28, 2022	BUY	Strong Buy -15.2% avg upside 20 analysts	$114.00 65.60% Downside	+28.9%	·
SRPT Sarepta Therapeutics	Sep 15, 2021	BUY	Buy +223.8% avg upside 50 analysts	—	+31.7%	·
GILD Gilead Sciences	Jan 04, 2021	BUY	Strong Buy -27.3% avg upside 66 analysts	—	+25.3%	·
INCY Incyte	Jan 04, 2021	BUY	Buy -5.9% avg upside 49 analysts	—	-16.9%	·
QURE uniQure	Jun 25, 2020	HOLD	Strong Buy +121.1% avg upside 30 analysts	—	-37.1%	·
MIRM Mirum Pharmaceuticals	Dec 16, 2019	BUY	Strong Buy +48.1% avg upside 24 analysts	$27.00 68.33% Downside	+3.9%	·
SGMOQ Sangamo Therapeutics	Nov 09, 2018	HOLD	Buy +9563.8% avg upside 16 analysts	$18.00 15417.27% Upside	·	·
EDIT Editas Medicine	Oct 09, 2018	HOLD	Buy +398.5% avg upside 33 analysts	—	-28.3%	·
TECX Tectonic Therapeutic	Oct 09, 2018	BUY	Strong Buy +176.5% avg upside 24 analysts	$35.00 76.91% Upside	-42.0%	·
CRSP Crispr Therapeutics AG	Oct 09, 2018	HOLD	Buy +45.6% avg upside 41 analysts	—	-0.3%	·
KPTI Karyopharm Therapeutics	May 04, 2017	BUY	Strong Buy +2682.1% avg upside 18 analysts	$16.00 2316.90% Upside	·	·
TCRT Alaunos Therapeutics	Jan 11, 2017	HOLD	Buy +723.4% avg upside 13 analysts	—	·	·
MNKD MannKind	May 13, 2014	HOLD	Buy +104.0% avg upside 22 analysts	—	-44.8%	·

🔒 30 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Whitney Ijem — Frequently Asked Questions

How accurate are Whitney Ijem's stock ratings?

Based on the calls 13Foresight could measure, about 38% of Whitney's ratings were profitable over a one-year hold, with an average return of -5.2% per rating, or -6.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Whitney ranked on 13Foresight?

Whitney Ijem is currently ranked #2755 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Whitney cover?

Whitney most recently has ratings on WVE, PHAR, BEAM, BMRN, NGNE, ALNY, GUTS, MAZE, QNRX, RCKT, BBIO, OCGN and 23 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Whitney Ijem

Rating Distribution

Welcome to 13Foresight!